Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

46.4K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.4K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

614
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
614
Retroviruses02:33

Retroviruses

12.6K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
12.6K
Drug Regulation01:25

Drug Regulation

1.6K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.6K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.1K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Exploratory In Silico Analysis of <i>Chlamydia trachomatis</i>-Induced Inflammatory, Interferon, and ECM Transcriptional Programs and Their Translational Context in TCGA Ovarian Cancer.

Cancers·2026
Same author

Model-Based Virtual Clinical Trial Reveals Renal Impairment and Body Size as Key Determinants of Pharmacokinetic Variability and Drug-Drug Interaction Risk in Propranolol Therapy.

Pharmaceutics·2026
Same author

Repurposing Antiretroviral Drugs for Urological Cancers: Differential Effects of Protease Inhibitors and NNRTIs on Prostate and Bladder Cancer Cells.

Cells·2026
Same author

Dual-Acting Vitamin B<sub>3</sub>-Melanostatin Neuropeptide Hybrids as Potent Modulators of the Dopamine D<sub>2</sub> Receptors with Neuroprotective Activity.

Journal of medicinal chemistry·2026
Same author

Recent advances in the development of selective hMAO-B inhibitors for neurodegenerative diseases: An update from 2020 to present.

European journal of medicinal chemistry·2026
Same author

18 kDa TSPO-mediated neurosteroidogenesis controls cholesterol homeostasis in tuning microglia response to inflammatory stimulus.

Biochimica et biophysica acta. Molecular basis of disease·2026

Related Experiment Video

Updated: Aug 13, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.9K

Efavirenz: History, Development and Future.

Bárbara Costa1,2,3, Nuno Vale1,2,3

  • 1OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.

Biomolecules
|January 21, 2023
PubMed
Summary
This summary is machine-generated.

Efavirenz, a key HIV-1 treatment, was studied at a reduced 400 mg dose versus the standard 600 mg dose. The lower dose showed comparable effectiveness with fewer side effects, suggesting potential for improved HIV management.

Keywords:
HIVNNRTIantiviral therapyclinical trialsefavirenz

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.4K
Fabrication and Characterization of Griffithsin-modified Fiber Scaffolds for Prevention of Sexually Transmitted Infections
12:21

Fabrication and Characterization of Griffithsin-modified Fiber Scaffolds for Prevention of Sexually Transmitted Infections

Published on: October 31, 2017

7.6K

Related Experiment Videos

Last Updated: Aug 13, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.9K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.4K
Fabrication and Characterization of Griffithsin-modified Fiber Scaffolds for Prevention of Sexually Transmitted Infections
12:21

Fabrication and Characterization of Griffithsin-modified Fiber Scaffolds for Prevention of Sexually Transmitted Infections

Published on: October 31, 2017

7.6K

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Virology

Background:

  • Efavirenz (Sustiva®) is a first-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) approved in 1998 for HIV-1 treatment.
  • The initial dosing regimen evolved from multiple capsules to a single 600 mg tablet, but this dose was linked to suboptimal viral suppression and toxicity.
  • Clinical observations indicated that a reduced efavirenz dose might maintain efficacy while mitigating adverse effects and cost.

Purpose of the Study:

  • To compare the efficacy and safety of a reduced efavirenz dose (400 mg) against the standard dose (600 mg) in antiretroviral-naïve HIV-infected individuals.
  • To evaluate if a lower efavirenz dosage could maintain virologic suppression and reduce toxicity.
  • To assess the overall effectiveness and tolerability of a modified efavirenz regimen.

Main Methods:

  • The ENCORE1 study involved antiretroviral-naïve individuals with HIV-1 infection.
  • Participants were randomized to receive either a reduced dose of efavirenz (400 mg once daily) or the standard dose (600 mg once daily), both in combination with two nucleoside reverse transcriptase inhibitors (NRTIs).
  • Efficacy and safety endpoints were monitored throughout the study period.

Main Results:

  • The reduced efavirenz dose (400 mg) demonstrated non-inferiority to the standard dose (600 mg) in terms of HIV suppression.
  • The 400 mg efavirenz regimen was associated with a lower incidence of adverse events and improved tolerability.
  • Plasma efavirenz concentrations were more favorable with the reduced dose, correlating with better outcomes.

Conclusions:

  • A reduced daily dose of 400 mg efavirenz is effective and safer than the standard 600 mg dose for treating HIV-1 infection in treatment-naïve individuals.
  • The findings support the optimization of efavirenz dosing to improve patient outcomes and reduce treatment-related toxicities.
  • While newer agents like INSTIs are emerging, efavirenz may still have roles in pre-exposure prophylaxis (PrEP) and drug repurposing.